<DOC>
	<DOCNO>NCT01902628</DOCNO>
	<brief_summary>This prospective observational study evaluate efficacy safety Mircera ( methoxy polyethylene glycol-epoetin beta ) chronic kidney disease patient dialysis renal anemia . Patients initiated treatment Mircera accord Summary Product Characteristics standard clinical practice follow 10 month .</brief_summary>
	<brief_title>OPTIMA : An Observational Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Patients With Chronic Kidney Disease Stages 3 &amp; 4 Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Patients chronic kidney disease ( CKD ) dialysis renal anemia ( CKD Stages 3 &amp; 4 ) Initiated Mircera treatment ( patient may receive Mircera treatment 3 month study enrollment ) Life expectancy &gt; 10 month Malignant disease Significant acute bleed Poorly control hypertension Blood transfusion previous 2 month Hypersensitivity Mircera excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>